Program
zumilokibart
In AbbVie’s pipeline, IL-13
. Its studies are mostly in Dermatitis, Atopic · Asthma, led by AbbVie.
Furthest: phase 2, since Apr 29, 20244 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 44 open or running | phase 2since Apr 29, 2024 | Apr 29, 2024 | Nov 2026phase 2 · NCT06395948 |
- Named in AbbVie’s own pipeline as
Zumilokibart
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 29, 2024First study: phase 2 study in Dermatitis, AtopicFirst studyNCT06395948 · 470 enrolled · United States, Canada, Czechia and more
- Mar 27, 2025Phase 1 study in AsthmaNCT06920901 · 31 enrolled · United States, United Kingdom
- May 26, 2025Phase 2 study in Dermatitis, AtopicNCT07003425 · 350 planned · United States, Canada, Czechia and more
- Jun 11, 2025Phase 1 study in Dermatitis, AtopicNCT07027527 · 86 enrolled · Australia, Canada, New Zealand
Ahead
- Nov 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT06395948
- Dec 2029Primary completion: phase 2 study in Dermatitis, AtopicNCT07003425
TargetBeta
“IL-13”the company's pipeline, read by Claude · source
Other programs on IL13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lebrikizumabrule | Eli Lilly | phase 4 | 44 |
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| ompekimig | Pfizer | phase 2 | 3 |
| GHZ339 | Novartis | phase 2 | 1 |
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07027527Dermatitis, Atopic · Australia, Canada, New Zealand | 1 | Active, not recruiting | Aug 29, 2026 | 86 |
| NCT07003425Dermatitis, Atopic · United States, Canada, Czechia and more | 2 | Recruiting | Dec 2029 | 350 |
| NCT06920901Asthma · United States, United Kingdom | 1 | Active, not recruiting | Sep 17, 2026 | 31 |
| NCT06395948Dermatitis, Atopic · United States, Canada, Czechia and more | 2 | Active, not recruiting | Nov 2026 | 470 |
How it is read
Names in the registry
- “APG777”, 6 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.